Genes May Predict Which Children With Heart Muscle Disease Face the Worst Outcomes

Dilated cardiomyopathy is one of the most feared diagnoses in pediatric cardiology. The heart’s main pumping chamber, the left ventricle, stretches and thins until it can no longer eject blood efficiently, and children may spiral into progressive heart failure within months or years. For decades, doctors could describe the condition but could rarely explain why one child deteriorates rapidly while another stabilizes on medication. A new retrospective study from a major tertiary children’s hospital in China adds a crucial piece to that puzzle, showing that the answer may lie, at least in part, in the child’s DNA.

Researchers at the Children’s Hospital of Fudan University in Shanghai analyzed 77 children with a dilated cardiomyopathy phenotype who had all undergone genetic testing at their center. The team, led by Jialing Liu, Chen Chu, and Yixiang Lin, with Huijun Wang and Fang Liu as corresponding authors, set out to map the genetic landscape of pediatric dilated cardiomyopathy in a Chinese population and, more importantly, to determine whether genetic results carry any prognostic weight. Their findings, published in BMC Pediatrics, suggest that they do.

The technical foundation of the study rests on next-generation sequencing. The children underwent clinical exome sequencing or whole-exome sequencing, approaches that read the protein-coding regions of the genome where disease-causing mutations in heart muscle genes typically hide. Every variant detected was classified according to the guidelines of the American College of Medical Genetics and Genomics, the internationally accepted framework that sorts genetic changes into categories ranging from benign to pathogenic based on evidence such as population frequency, predicted protein effects, and previous disease associations. Only variants graded as pathogenic or likely pathogenic counted toward a positive genetic result, while ambiguous variants of uncertain significance were excluded from the genotype-positive designation.

That rigorous classification matters, because the yield was meaningful but not overwhelming. Pathogenic or likely pathogenic variants were identified in 17 of the 77 children, a detection rate of 22.1 percent. The most frequently implicated genes were FLNC, LMNA, TNNT2, and TTN, a roster that will be familiar to anyone who follows cardiovascular genetics. TTN, which encodes titin, the gigantic spring-like protein that gives cardiac muscle cells their elastic recoil, is the most common gene implicated in adult dilated cardiomyopathy. LMNA, which produces the lamin proteins that scaffold the cell nucleus, is notorious for producing aggressive disease with conduction system problems and a high risk of sudden cardiac death. FLNC and TNNT2 encode filamin C and cardiac troponin T respectively, proteins central to the structural integrity and contractile machinery of the heart cell.

The study’s central result emerged when the researchers split their cohort into genotype-positive and genotype-negative groups and followed them over time. Using Kaplan-Meier survival analysis, the standard statistical method for tracking how many patients remain free of a defined event over a period, they found that children carrying disease-causing variants fared significantly worse than those without them. Among the genotype-positive children, only 64.7 percent remained free of death or cardiac transplantation at one month after diagnosis. That figure fell to 47.1 percent at one year and 35.3 percent at three years, a steep and sobering decline that underscores how unforgiving genetically driven disease can be in young patients.

To quantify the risk more precisely, the team turned to Cox proportional hazards regression, a modeling technique that estimates how a given factor changes the instantaneous risk of an event while accounting for follow-up time. In univariable analysis, genotype-positive status was associated with roughly a 2.3-fold higher risk of death or cardiac transplantation, with a hazard ratio of 2.29 and a 95 percent confidence interval of 1.06 to 4.94, reaching statistical significance at a P value of 0.035. When the investigators adjusted the model for age at diagnosis and New York Heart Association functional class, a clinical measure of heart failure severity, the association weakened and no longer reached the conventional threshold for significance, yielding a hazard ratio of 2.10 with a confidence interval of 0.97 to 4.55 and a P value of 0.060.

That attenuation is worth examining carefully, because it illustrates a perennial tension in clinical research. The adjusted analysis suggests that some of the apparent genetic risk may overlap with how sick children already appear at diagnosis, since older age and worse functional class are themselves markers of advanced disease. Yet a hazard ratio hovering just above 2 with a confidence interval that barely crosses 1.0 is hardly evidence of no effect; with only 17 genotype-positive patients, the study was almost certainly underpowered to fully separate genetic risk from clinical severity. The authors themselves frame the conclusion conservatively, stating that genotype-positive patients showed poorer event-free survival and that genetic evaluation may provide useful information for prognostic assessment rather than claiming genetics independently predicts outcome.

Why does this matter for clinical practice? Pediatric dilated cardiomyopathy is rare and genetically heterogeneous, and its management has long been dominated by phenotype: echocardiographic measurements of left ventricular size and ejection fraction, biomarkers such as NT-proBNP and cardiac troponin I, and functional classification. The study’s abbreviation list hints at the full diagnostic arsenal, from cardiac magnetic resonance imaging with late gadolinium enhancement to detailed volumetric indices of ventricular remodeling. Genetic testing has been creeping into routine care, but its role has often been justified on diagnostic and family-screening grounds alone. Demonstrating that a positive genotype tracks with worse event-free survival gives clinicians a second, prognostic reason to order the test, potentially supporting earlier escalation of therapy, closer surveillance, or timely referral for advanced options such as mechanical circulatory support or transplantation evaluation.

The family dimension is equally consequential. Identifying a pathogenic variant in a child with dilated cardiomyopathy converts an isolated case into a heritable condition, opening the door to cascade testing of parents and siblings. Because many of the implicated genes act in an autosomal dominant fashion, a parent may carry the same variant, sometimes with subtle or undiagnosed cardiac involvement, and other relatives may harbor the mutation before any symptoms appear. In diseases where early detection can change the trajectory, that knowledge is not academic. It is also why the 22.1 percent detection rate, while lower than some figures reported in adult cohorts, still represents a substantial fraction of children whose families can now receive targeted genetic counseling.

Like all retrospective single-center studies, this work has limits the authors acknowledge implicitly through their design. The cohort was modest, testing was performed at one tertiary Chinese center that may see disproportionately severe cases, and the genetic technologies used, focused as they are on exomes, can miss variants in non-coding regions, structural rearrangements, or copy number changes that newer genome sequencing approaches would capture. The genotype-negative group may also contain children with variants that current knowledge cannot yet classify as pathogenic. Still, the study fills a genuine gap, since the genetic spectrum and prognostic significance of dilated cardiomyopathy in Chinese children had remained incompletely characterized. As sequencing costs continue to fall and variant databases grow more diverse, the hope is that genetic testing will move from an optional add-on to a standard pillar of pediatric cardiomyopathy care, helping clinicians decide not only what a child’s heart is doing today, but what it is likely to do tomorrow.

Subject of Research: Genetic testing and prognosis in pediatric dilated cardiomyopathy

Article Title: Clinical characteristics, genetic findings, and outcomes in 77 Chinese children with dilated cardiomyopathy who underwent genetic testing: a retrospective study

Article References: Liu, J., Chu, C., Lin, Y., Wang, F., He, L., Zhao, Q., Zhao, L., Sun, S., Zheng, Y., Wang, J., Chen, W., Yan, G., Zhang, Z., Wang, H., & Liu, F. (2026). Clinical characteristics, genetic findings, and outcomes in 77 Chinese children with dilated cardiomyopathy who underwent genetic testing: a retrospective study. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07793-4

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07793-4

Keywords: dilated cardiomyopathy, pediatric cardiology, genetic testing, FLNC, LMNA, TNNT2, TTN, event-free survival, Kaplan-Meier analysis, Cox regression, ACMG variant classification, heart failure